Apollomics, Inc.
APLM
NASDAQ·Healthcare·Biotechnology·Mkt cap $60.4M
$27.50
▼ -0.02%
P/E
—
Mkt Cap
$60.4M
52-Wk Range
$5.20–$42.12
52-Week Range
$5.20 - $42.12
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 406.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary selective c-Met inhibitor technology with APL-101
- Diversified pipeline targeting multiple cancer types and geographies
- Strong R&D capabilities and international presence in key markets
- Focus on unmet medical needs in oncology with significant market opportunities
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Strong growth ahead
Clinical trial advancement and regulatory approvals for lead candidates
Value
Valuation data unavailable
Momentum
Hot
+96.4% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying APLM right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 24, 2026
Most recent quarter reported revenue of $0. Reported EPS of $3.80.
Reported EPS · last 4Q
Q4 25
$3.80
Q2 25
-$11.37
Q4 24
-$16.92
Q2 24
-$37.56
Revenue trend · last 8Q
—
—
-18%
+222%
+262%
-571%
+381%
-100%
Q2 22
Q4 22
Q2 23
Q4 23
Q2 24
Q4 24
Q2 25
Q4 25
$595.0K
-$272.0K
$488.0K
$333.0K
$1.8M
-$1.6M
$8.5M
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How APLM stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related